CNBC January 14, 2024
Key Points
– An established but promising group of cancer drugs was a red-hot market in 2023, and more acquisitions and advancements are expected in the year ahead.
– That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco.
– Researchers say those drugs could have less toxicity – or unwanted effects on your body that could lead to harm – than standard chemotherapy.
SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead.
That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco, the nation’s largest gathering of biotech and pharmaceutical...
Today's Sponsors
Today's Sponsor